Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Elena Xerxa
Comprehensive Data-Driven Assessment of Non-Kinase Targets of Inhibitors of the Human Kinome
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Data sets of human and mouse protein kinase inhibitors with curated activity data including covalent inhibitors
PKIs are intensely investigated as drug candidates in different therapeutic areas [1–3]. The human kinome comprises 518 kinases [4]. Currently, PKIs with high-confidence activity data are available for more than 400 kinases, as further discussed below, and most of these extensively or still preliminarily explored kinases are considered as drug targets for the treatment of a variety of acute or chronic diseases [1–3]. Thus far, 71 human PKIs are approved as drugs by the US FDA [5].
Systematic Analysis of Covalent and Allosteric Protein Kinase Inhibitors
Open AccessArticle by Elena Xerxa , Oliver Laufkötter and Jürgen Bajorath * LIMES Program Unit Chemical Biology and Medicinal Chemistry, Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 5/6, D-53115 Bonn, Germany * Author to whom correspondence should be addressed.
A Role for STOML3 in Olfactory Sensory Transduction
Research ArticleResearch Article: New Research, Sensory and Motor Systems Emilio Agostinelli, Kevin Y. Gonzalez-Velandia, Andres Hernandez-Clavijo, Devendra Kumar Maurya, Elena Xerxa, Gary R.
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma
Abstract The BCL-2 inhibitor venetoclax has only limited activity in DLBCL despite frequent BCL-2 overexpression. Since constitutive activation of the B cell receptor (BCR) pathway has been reported in both ABC and GCB DLBCL, we investigated whether targeting SYK or BTK will increase sensitivity of DLBCL cells to venetoclax.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Elena
Contact Elena, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack